Collectively, these findings indicate that decreased serum STOX1 tracks adverse metabolic and inflammatory profiles in obesity and support its potential utility as a noninvasive biomarker of adipose tissue inflammation in overweight/obese individuals. This evidence concerns the gene STOX1 and obesity due to melanocortin 4 receptor deficiency.